Treatment.com AI Announces New Medical Education Suite to Enhance Clinical Skills Training Through AI-Simulated Patients
Treatment.com
AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) ('Treatment') is pleased to announce that it has released its latest version of the Medical Education Suite (MES). The University of Minnesota Medical School has successfully completed a live deployment of
Treatment.com
AI's new Medical Education Suite (MES), an AI-powered clinical skills assessment platform designed to support medical schools in delivering scalable, rigorous, and cost-effective Objective Structured Clinical Examinations (OSCEs).
The deployment, conducted with over 240 third-year medical students, marked the first large-scale implementation of computer-simulated patient cases developed through the Global Library of Medicine (GLM), a clinician-built medical knowledge engine. The exams ran with complete technical reliability during deployment, as well as integrating seamlessly into the school's existing OSCE workflow.
'Our goal is to support medical schools by applying our clinical experience and AI expertise to real educational challenges.' stated Dr. Kevin Peterson, Founder and Chief Medical Officer of
Treatment.com
AI. 'The Medical Education Suite reflects years of development in diagnostic reasoning and knowledge engineering. By introducing structured, AI-simulated patients alongside live simulated patients, and offering objective real-time scoring, we're helping students build stronger clinical skills in the classroom and giving educators the trusted healthcare education software needed to teach and assess clinical content and behavioral approaches to complex clinical problems with confidence.'
The MES is a scalable platform designed to reduce administrative and faculty time, improve objectivity, increase evaluation consistency, and provide a robust digital infrastructure to support both live and AI-simulated formats. The focus of the platform is to help enhance the clinical skills of our next generation of healthcare professionals. By incorporating curated AI-generated cases and the supportive services provided by Treatment, the system enables:
'Partnering with
Treatment.com
AI gave us the opportunity to explore how clinically governed AI can strengthen the way we assess and support student learning. The MES allowed us to deliver a high-stakes OSCE at scale, while ensuring consistent, objective evaluation aligned with our academic standards. The MES represents a meaningful step forward in the evolution of medical education.' said Professor Claudio Violato, Assistant Dean, University of Minnesota Medical School. 'We look forward to sharing our findings.'
The MES combines AI-simulated patients with automated feedback, helping faculty assess diagnostic and management reasoning, clinical prioritization, and documentation quality, all mapped to learning objectives. Early feedback suggests that the platform enhances the student learning experience and strengthens the reliability of OSCE results.
Preliminary results of the accuracy and precision of the GLM as applied in the MES platform were presented at the AAMC's 2025 Group on Information Resources meeting. Prof. Violato, Dr. Peterson, and their respective teams are preparing further scientific publications detailing the methodology, deployment, and outcomes of the UMN program.
Treatment.com AI is engaging with a wide variety of other schools, with the goal to extend the MES offering across North America, the UK, and to other international OSCE markets.
About
Treatment.com
AI Inc.
Treatment.com AI is a company utilizing AI (artificial intelligence) and best clinical practices to positively improve the healthcare sector and impact current inefficiencies and challenges. With the input of hundreds of healthcare professionals globally,
Treatment.com
AI has built a comprehensive, personalized healthcare AI engine — the Global Library of Medicine (GLM). With more than 10,000 expert medical reviews, the GLM delivers tested clinical information and support to all healthcare professionals as well as providing recommended tests (physical and lab), imaging and billing codes. The GLM helps healthcare professionals (doctors, nurses or pharmacists) reduce their administrative burden; creates more time for needed face-to-face patient appointments; and enables greater consistency in quality of patient support.
Treatment.com
AI's GLM platform, through supporting healthcare professionals, allows for the inclusion of disenfranchised communities.
Learn more at:
or contact
.
About University of Minnesota Medical School
Founded in 1888, the University of Minnesota Medical School is one of the nation's largest, with three campuses in Minneapolis, Duluth, and St. Cloud. It enrolls first- and second-year students at Duluth and St. Cloud, and carries clinical training at the Twin Cities campus and affiliated hospitals. The school educates future physicians through MD, graduate, undergraduate, and continuing professional development programs, supported by over 3,000 faculty members and 20+ research centers and institutes. Its core mission is to improve health through exceptional education, compassionate patient care, and leading-edge biomedical research, particularly focusing on primary care, specialty medicine, rural communities, and American Indian/Alaska Native populations. The school is nationally recognized for its NIH-funded research (ranked #21 overall, #2 among public medical schools) and emphasizes interprofessional, community-based training while promoting equity and access across diverse populations.
Learn more at:
FOR ADDITIONAL INFORMATION, CONTACT:
Dr. Essam Hamza, CEO –
Treatment.com
AI Inc.
Email:
Media inquiries:
treatment.com
Sales:
Call: +1 (612) 788-8900 / Toll-Free USA/Canada: +1 (888) 788-8955
Cautionary Statement
This news release contains forward-looking statements that are based on
Treatment.com
AI's expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to the implementation of its shareholder communications initiative and the timing thereof. Although
Treatment.com
AI believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements, and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and
Treatment.com
undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law.
The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
3 hours ago
- Business Wire
Sonendo Strengthens Leadership Team With Promotion of John McGaugh to Chief Operating Officer
LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Sonendo, Inc. ('Sonendo' or the 'Company') (OTC Pink: SONX), a leading dental technology company and developer of the GentleWave® System, today announced the promotion of John McGaugh to Chief Operating Officer. Mr. McGaugh previously held the position of Senior Vice President of Operations. 'Since Sonendo embarked on its strategic reset in early-2024, the Company has stabilized revenue, generated significant leverage in gross margin, and meaningfully lowered total operating expenses, adjusted EBITDA loss and cash burn,' stated Bjarne Bergheim, President and Chief Executive Officer of Sonendo. 'John has been a significant contributor to all those improvements, and we expect he will continue to drive additional operating leverage as the Company continues to execute its plans to achieve profitability. John is a valuable member of the team, and I am excited to see him take on the role of Chief Operating Officer.' In addition to his previous responsibilities overseeing quality, manufacturing, supply chain, and technical services operations, Mr. McGaugh now has oversight of Sonendo's capital and consumables sales teams and commercial operations. Mr. McGaugh has over 20 years overseeing global manufacturing operations. He joined Sonendo in May 2023 and has been instrumental in leading significant operational efficiencies with console assembly and procedure instrument margin contributions. Prior to his time at Sonendo, Mr. McGaugh served as a multi-site operational leader for Abbott Vascular. In addition to his experience at Abbott, Mr. McGaugh has held leadership roles at Boston Scientific and American Medical Systems. About Sonendo Sonendo is a commercial-stage medical technology Company focused on saving teeth from tooth decay, the most prevalent chronic disease globally. Sonendo develops and manufactures the GentleWave® System, an innovative technology platform designed to treat tooth decay by cleaning and disinfecting the microscopic spaces within teeth without the need to remove tooth structure. The system utilizes a proprietary mechanism of action, which combines procedure fluid optimization, broad-spectrum acoustic energy and advanced fluid dynamics, to debride and disinfect deep regions of the complex root canal system in a less invasive procedure that preserves tooth structure. The clinical benefits of the GentleWave System when compared to conventional methods of root canal therapy include improved clinical outcomes, such as superior cleaning that is independent of root canal complexity and tooth anatomy, high and rapid rates of healing and minimal to no post-operative pain. In addition, the GentleWave System can improve the workflow and economics of dental practices. For more information about Sonendo and the GentleWave System, please visit To find a GentleWave doctor in your area, please visit Forward Looking Statements This news release includes forward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, the Company's ability to continue to drive additional operating leverage and/or execute its plans to achieve profitability, whether as a result of Mr. McGaugh or otherwise. You are cautioned that such statements are not guarantees of future performance and that our actual results may differ materially from those set forth in the forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions; speak only as of the date they are made; and, as a result, are subject to risks and uncertainties that may change at any time. Factors that could cause the Company's actual results to differ materially from these forward-looking statements are described in detail in the 'Risk Factors' section of the Company's Annual Report on Form 10-K that was filed with the Securities and Exchange Commission on March 26, 2025. Such filings are available at The Company undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent developments, events, or circumstances, except as may be required under applicable securities laws. Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.
Medscape
11 hours ago
- Medscape
Managing Primary Care of Patients After Cancer Treatment
The good news about cancer is that there are increasing numbers of people who are surviving after treatment, in some cases due to newer medicines and, in others, due to screening detecting the disease earlier. As of January 1, about 18.6 million people in the US had a history of oncologic treatment, a figure expected to exceed 22 million by 2035, researchers at the American Cancer Society estimated in a new report. While the estimate excludes most in situ carcinoma and basal cell or squamous cell skin cancers, it still shows how primary care clinicians will likely face increasing demands to help patients manage the aftermath of their cancer treatment. Some cancers appear to be showing up more in younger people, perhaps in part due to sedentary lifestyles and poor diet. Research found excess body weight may play a role in global increases seen in early-onset breast, pancreatic, colorectal, and kidney cancers. And treatments for cancer have been undergoing radical changes. Older chemotherapies that stop fast-growing cells, such as cancerous ones, remain widely used, but many new kinds of drugs have been introduced, sometimes only with emerging data available on their safety and benefits. These include immune checkpoint inhibitors, chimeric antigen receptor T-cell therapies, and new forms of monoclonal antibodies. 'It's an exploding field' of treatments, said Kimberly S. Peairs, MD, the vice chair for clinical affairs at Johns Hopkins School of Medicine, Baltimore. Yet there has not been much focus in US medicine in general on what happens when patients cycle back to being seen primarily by their primary care clinicians after treatment. Peairs in 2015 founded the Primary Care for Cancer Survivors Program , which has served as a model for physicians elsewhere seeking to help bridge gaps that might otherwise happen in patient care. For example, Ilana Yurkiewicz, MD, of Stanford University School of Medicine sought advice from Peairs when she sought to create a more unified approach to caring for patients who have had cancer treatments. Yurkiewicz has worked closely with Natasha Steele, MD, a Stanford colleague who is a former lymphoma patient. In an interview with Medscape Medical News , Steele noted how patients can face a jarring change at the end of treatment. They transition from relying heavily on oncologists' expertise during their life-threatening illness to needing to resume participation in managing aspects of their own care. 'During cancer treatment, patients have to put their lives in the hands of their oncologists and trust they are safe,' Steele said. 'But survivorship is a paradigm shift where we're really trying to empower patients with information and skills to manage some of their health risks longitudinally, and this can be challenging for a lot of reasons.' For primary care clinicians, the changes in treatment and outcomes are allowing them to participate in one of the most rapidly advancing fields of medicine. For example, the National Comprehensive Cancer Network (NCCN) updated its guidelines 241 times last year. Clinicians in primary care can also rely on many tools like UptoDate and continuing medical education courses to aid with this challenge. Physicians can help patients adjust to their 'new normal' life after cancer treatment, Peairs said. 'We're not asking primary care people to be oncologists,' she said. Below are three tips for primary care clinicians based on interviews with physicians who have significant expertise in oncology and in the emerging field known as survivorship. 1. Try reaching your patients about steps to prevent recurrence or future cancers. Primary care clinicians can help get important messages through to patients who may struggle to keep track of follow-up care, said Kathleen N. Mueller, MD, the system director for integrative medicine and cancer survivorship for Nuvance Health, a seven-hospital health system in Connecticut and southeastern New York. Muller also serves on the board of directors of the American Academy of Family Physicians. 'When you're undergoing treatment for cancer, it's really difficult to process information,' Mueller said. 'It is an overwhelming diagnosis.' In many cases, people did not suspect they had cancer before their diagnosis. 'Now, all of a sudden, they're thinking about their mortality,' she said. 'They may not get all the information that's communicated to them. So they might miss the fact that they're supposed to get, for example, a mammogram every 6 months with an MRI.' A key to success with these talks about preventing recurrence is finding a way to make sure patients hear the message, such as by discussing different steps at different visits, said Crystal S. Denlinger, MD, the chief executive officer of NCCN. 'It's less about having an exact knowledge and more about knowing where to go to get the knowledge you need,' Denlinger said. 'You don't need to tackle it all at every visit. During one visit, you could ask somebody about how physically active they are and then talk about the fact that physical activity can lower the rate of development of cancer, and for certain cancers, could actually lower the rate of recurrence.' Another visit could be an opportunity to discuss nutrition. 'Maybe you ask them about their diet and how much processed food they're eating, how many fruits and vegetables they're eating,' Denlinger said. 'You don't have to tackle the whole mountain. Start with a few steps.' Denlinger also said it's important to acknowledge the good habits patients already have, such as getting enough physical activity. 2. Provide patients opportunities to discuss how they are feeling. Steele said she works to provide a 'safe space' where patients can talk about what they are going through. 'After cancer treatment, a lot of people don't feel like the person they were before cancer,' Steele said, adding that this can be distressing for them. 'The way I approach this with my patients is I try to normalize the challenges and the trauma of cancer and give them the skills to figure out how to use parts of the experience in a meaningful way,' she said. Primary care clinicians have a chief role in helping patients with concerns about recurrence and the challenges of managing life after cancer treatment, Denlinger said. Anxiety is likely to crop up 'in those quiet moments' after the most challenging phases of cancer treatment are done, Denlinger said. After diagnosis, patients often shift into a 'I've got to fight the cancer' mindset, needed to help them focus and get through treatments. The demands of cancer care, along with the attendant disruptions to home and family life, can provide some degree of distraction. After treatment, patients disconnect with their constant oncology engagement, she said. 'Now they're returning back to the life that they had before they had cancer,' Denlinger said. 'This may be a time where primary care providers are an important resource to address some of this post-treatment anxiety, as they're sort of processing all the things that they've been through. Fear of recurrence is real, and it needs to continue to be assessed.' Peairs and her colleagues at Johns Hopkins published a 2020 paper about the first 4 years of the Johns Hopkins Primary Care for Cancer Survivors Program. This paper included results from a survey of patients that found many sought help with emotional needs. These included fear of recurrence, reported by 64.2%; the challenge of living with uncertainty, 62.5%; and managing difficult emotions: anger, anxiety, and depression (53.1%). People may also have concerns about what their diagnosis means for their family members, Mueller said. For example, a woman diagnosed with breast cancer may be worried about her daughter's risk. Family physicians often build relationships with their patients over many years, and in many cases, know something about their relatives, giving them insights that oncologists couldn't be expected to have, Mueller said. 'It's the longitudinal, consistent relationship that we have,' she said. 3. Be aware that a patient's risk can change over time. It's important to check for changes in both your patients' family history and the guidelines for screening, Denlinger said. For example, a history done several years ago may not reflect recent diagnoses of cancer in a patient's family. There also are newer genetic tests, such as those for pancreatic cancer risks, that may be suitable for patients, she said.
Yahoo
11 hours ago
- Yahoo
AI-Powered Pathogen Detection App: Provisional Patent Filed by FendX CEO
Vancouver, British Columbia--(Newsfile Corp. - August 20, 2025) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D) (the "Company" or "FendX"), an innovative surface protection company developing their technology-based solutions to reduce the spread of harmful pathogens and support a cleaner, safer world, is pleased to announce that its CEO, Dr. Carolyn Myers, has filed a provisional patent application with the United States Patent and Trademark Office. The application, titled "AI Adaptive App Pathogen Detection Platform" dated June 25, 2025, will be assigned to FendX as part of its expanding portfolio of hygiene-related technologies. The invention described in the patent application is being designed to combine mobile-based imaging, biosensor technology, and artificial intelligence ("AI") to enable real-time detection of pathogens on surfaces using a mobile device such as a smartphone. The aim is to develop a portable, intelligent and user-friendly diagnostic tool for both consumer and professional use. "Traditional diagnostic methods are powerful but often take time to detect and identify pathogens, and they're usually limited to lab settings," said Dr. Carolyn Myers, FendX CEO and inventor. "This invention is part of our ongoing commitment to making surface protection smarter and I believe it shows how mobile devices and AI can work together to bring advanced pathogen detection directly to the user." About FendX Technologies Inc. FendX is a surface protection company leveraging its proprietary technology to develop product solutions that help reduce the spread of harmful pathogens in everyday environments. The Company is advancing an eco-friendly, smart sponge designed to deliver effective cleaning while minimizing environmental impact. This innovative product complements FendX's broader pipeline, which includes REPELWRAP™ film, a protective surface coating with repelling properties that significantly reduce adhesion and transmission of pathogens on high-touch surfaces, and a spray-based coating with similar functionality. Additionally, the Company is developing specialized catheter coatings, with its first coating being for Foley catheters. The Company holds an exclusive supply agreement for the eco-sponge and an exclusive license to certain intellectual property related to the use of the sponge, as well as exclusive worldwide licenses and intellectual property for its coating technologies. ON BEHALF OF THE COMPANY "Carolyn Myers"Carolyn MyersChief Executive Officer and Director Contacts: Dr. Carolyn Myers, CEO and Director1-800-344-9868investor@ For more information, please visit and the Company's profile on SEDAR+ at Neither the Canadian Securities Exchange nor the Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Statements This news release contains certain forward-looking statements within the meaning of Canadian securities legislation, including with respect to: the plans of the Company; statements regarding the provisional patent application, invention and goals related to the development of the invention;; and products under development and any pathogen reduction benefits related thereto. Although the Company believes that such statements are reasonable, it can give no assurance that such expectations will prove to be correct. These statements are only predictions and involve known and unknown risks which may cause actual results and the Company's plans and objectives to differ materially from those expressed in the forward-looking statements, including: risks that the provisional patent application may not receive regulatory approval; adverse market conditions; risks and uncertainties associated with the Company's ability to raise additional capital to complete all of its planned activities including development of the invention;; risks related to research and development activities for each of the film, spray formulation and catheter coating, including successful completion of real world performance testing and scale-up initiatives; risks that the Company may not expand its product pipeline or execute its business development and growth plans; risks that the Company's products, including the eco-friendly sponge, may not be commercialized, and if they are commercialized, that they may not be accepted and adopted by the public; the risk that the Company will not obtain necessary approvals and/or clearances as anticipated or at all; the effects of government regulation on the Company's business; risks associated with the Company's ability to obtain and protect rights to its IP, including the provisional patent application to be assigned to the Company; product candidates only being in formulation/reformulation stages; limited operating history; dependence on collaborative partners, licensors and others; effect of general economic and political conditions; and other factors beyond the Company's control. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity or performance. Further, any forward-looking statement speaks only as of the date on which such statement is made and, except as required by applicable law, the Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time, and it is not possible for management to predict all of such factors and to assess in advance the impact of such factors on the Company's business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statement. Readers should consult all of the information set forth herein and should also refer to the risk factor disclosure outlined in the Company's filings with the British Columbia Securities Commission on SEDAR+ at To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
